Retatrutide (LY3437943) is an investigational peptide being studied as a tri-receptor agonist that engages GLP-1, GIP, and glucagon receptors. It is evaluated strictly in preclinical and clinical research settings to explore its effects on metabolic pathways, appetite regulation, and energy expenditure.

Note: This material is provided for laboratory research purposes only. It is not an approved drug or product for medical use.

• Designed to co-activate GLP-1, GIP, and glucagon receptors.
• GLP-1/GIP pathways are researched for effects on satiety and insulin dynamics.
• Glucagon receptor engagement is studied for influences on energy expenditure and lipid metabolism.
• Overall metabolic effects, safety, and pharmacology remain subjects of ongoing research.

• Metabolic pathway studies (energy balance, lipid and glucose metabolism).
• Appetite and satiety signaling models.
• Comparative receptor-agonism research vs. single/dual agonists.
• Pharmacokinetic/pharmacodynamic characterization in non-clinical models.

• Retatrutide: Investigational tri-agonist (GLP-1 + GIP + glucagon).
• Tirzepatide: Approved medicine in some jurisdictions; dual-agonist (GLP-1 + GIP). References to tirzepatide here are for scientific context only.

Any comparative notes are mechanistic/contextual for lab discussions and should not be interpreted as guidance for treatment, dosing, or clinical decision-making.

GLP-1 and GIP are incretin hormones studied for roles in satiety and glucose regulation, while glucagon signaling is investigated for its impact on hepatic glucose output and energy expenditure. Multi-agonism research explores whether concurrent receptor engagement can modulate multiple metabolic axes.

These insights are relevant to metabolism research and are not medical guidance.

• For qualified laboratory personnel following institutional SOPs.
• Use appropriate PPE (gloves, eye protection, lab coat) and handle in a controlled environment.
• Store according to internal lab guidelines; protect from moisture and light; avoid repeated freeze–thaw when applicable.
• Research Use Only. Not for Human or Veterinary Use.

See peer-reviewed literature on GLP-1/GIP/glucagon receptor pharmacology and publicly available conference abstracts/manufacturer communications for investigational agents. Content here is for scientific/educational context only.